IBT-B.ST Stock — Price, Charts & Analysis

IBT-B.ST's trailing EPS is -SEK 5.30.

EPS, or earnings per share, shows how much profit Infant Bacterial Therapeutics AB (publ) generated for each share. IBT-B.ST's trailing EPS is -SEK 5.30, and investors usually prefer EPS that is positive and growing over time.

Infant Bacterial Therapeutics AB (publ) has a market cap of SEK 885.07M, making IBT-B.ST a small-cap stock based on the current market value shown on Worldtickers.

IBT-B.ST's latest stock price on Worldtickers is SEK 65.70. The latest move is SEK 0.70 or 1.08%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

IBT-B.ST's quote includes a latest price of SEK 65.70. The market open is SEK 65.10. Previous close is SEK 65.00. The intraday range is SEK 64.60 to SEK 65.80.

IBT-B.ST is up in the latest quote, with a move of SEK 0.70 or 1.08%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

No, IBT-B.ST does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -SEK 71.36M.

Gross margin is 0.00%. Margins show how efficiently Infant Bacterial Therapeutics AB (publ) turns revenue into profit.

Infant Bacterial Therapeutics AB (publ) carries SEK 0.00 and holds SEK 131.93M in cash.

IBT-B.ST holds SEK 131.93M on its balance sheet.

IBT-B.ST's book value per share is SEK 6.13.

Institutions hold 36.74% of IBT-B.ST shares. Insiders hold 14.52% of shares. Ownership mix helps investors understand how much of Infant Bacterial Therapeutics AB (publ) is held by professional investors and company insiders.

IBT-B.ST has 13.02M shares outstanding. Float shares are 11.23M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for IBT-B.ST, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

IBT-B.ST's trailing EPS is -SEK 5.30. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

IBT-B.ST trades at SEK 65.70. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Infant Bacterial Therapeutics AB (publ)'s fundamentals.

IBT-B.ST risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.36, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

IBT-B.ST should be compared with companies in Biotechnology. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) operates in Healthcare, specifically Biotechnology. Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its

IBT-B.ST trades on Stockholm. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

IBT-B.ST stock is priced in SEK on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Infant Bacterial Therapeutics AB (publ)'s official website listed on Worldtickers is www.ibtherapeutics.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Infant Bacterial Therapeutics AB (publ) employs about 6 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Infant Bacterial Therapeutics AB (publ) is headquartered in Stockholm, Sweden. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

IBT-B.ST is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

IBT-B.ST has traded between SEK 43.25 and SEK 84.30 over the past 52 weeks. At SEK 65.70, it is 22.06% below the high and 51.91% above the low. The 52-week range helps gauge long-term price momentum.

IBT-B.ST is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is SEK 65.49 and its 200-day moving average is SEK 55.18.

IBT-B.ST's RSI is 51.10. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

IBT-B.ST's latest RSI reading is 51.10, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for IBT-B.ST is near SEK 63.30. Key resistance is near SEK 69.40. Breaks above resistance or below support can change the short-term technical setup.

IBT-B.ST's nearest reported support level is SEK 63.30. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

IBT-B.ST's nearest reported resistance level is SEK 69.40. A breakout above resistance can improve momentum, especially when volume confirms the move.

IBT-B.ST trades about 7.49K shares daily on average. The latest displayed volume is 2.23K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

IBT-B.ST's MACD is -0.17, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

IBT-B.ST is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 51.10 (neutral). MACD is bearish. Nearest support is around SEK 63.30. Resistance is around SEK 69.40. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is SEK 65.78 (-0.12% from price). MA50 is SEK 65.49 (0.33% from price). MA200 is SEK 55.18 (19.06% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. IBT-B.ST's MA20 is SEK 65.78. MA50 is SEK 65.49. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

IBT-B.ST's pivot is near SEK 65.33. Support is near SEK 63.30. Resistance is near SEK 69.40. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for IBT-B.ST is near SEK 62.86. The next upper resistance zone is near SEK 69.40. These levels help define risk and possible follow-through zones after a breakout or breakdown.

IBT-B.ST's Bollinger range is roughly SEK 64.09 to SEK 67.47. Band width is near 5.13%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

IBT-B.ST's ATR-based typical daily range is about 3.72%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 2.23K shares. Average volume is about 7.49K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

IBT-B.ST's all-time high shown on Worldtickers is SEK 274.50. Its all-time low is SEK 21.70. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

IBT-B.ST has a beta of 0.36, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.